Verrica Pharmaceuticals Inc. (VRCA) NASDAQ
5.79
-0.11(-1.86%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.79
-0.11(-1.86%)
Currency In USD
| Previous Close | 5.9 |
| Open | 5.9 |
| Day High | 6.17 |
| Day Low | 5.79 |
| 52-Week High | 9.82 |
| 52-Week Low | 3.28 |
| Volume | 27,440 |
| Average Volume | 102,034 |
| Market Cap | 61.67M |
| PE | -5.26 |
| EPS | -1.1 |
| Moving Average 50 Days | 6.11 |
| Moving Average 200 Days | 5.9 |
| Change | -0.11 |
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
GlobeNewswire Inc.
Mar 05, 2026 1:00 PM GMT
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions,
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced t
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced t